摘要
目的:观察罗沙司他联合重组人促红素治疗肾性贫血患者的效果。方法:选取100例肾性贫血患者作为研究对象,按照随机数字表法分为观察组与对照组各50例。对照组给予重组人促红素治疗,观察组在对照组基础上联合罗沙司他治疗,比较两组T细胞亚群指标水平、血红蛋白(Hb)水平、白蛋白(Alb)水平、铁蛋白(SF)水平、炎性因子[白细胞介素(IL)-6、IL-8、C反应蛋白(CRP)]水平和不良反应发生率。结果:治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,且观察组高于对照组,两组CD8^(+)水平明显低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);治疗后,两组Hb、Alb、SF水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);治疗后,两组CRP、IL-6、IL-8水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:罗沙司他联合重组人促红素治疗肾性贫血患者可改善T细胞亚群相关水平,降低炎性因子水平,以及提高Hb、Alb、SF水平,效果优于单纯重组人促红素治疗。
Objective:To observe effects of Roxadustat combined with recombinant human erythropoietin in treatment of patients with renal anemia.Methods:100 patients with renal anemia were selected as the research objects,and were divided into observation group and control group according to the random number table method,50 cases in each group.The control group was treated with recombinant human erythropoietin,while the observation group was treated with Roxadustat on the basis of that of the control group.The T cell subsets-related index levels,the levels of hemoglobin(Hb),albumin(Alb),ferritin(SF),inflammatory factors[interleukin(IL)-6,IL-8,C-reactive protein(CRP)]and the incidence of adverse reactions were compared between the two groups.Results:After the treatment,the levels of CD4^(+),CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,and those of the observation group were higher than those of the control group;the CD8^(+)levels of the two groups were significantly lower than those before the treatment,and that of the observation group was higher than that of the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of Hb,Alb and SF in the two groups were higher than those before the treatment;those of the observation group were higher than those of the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of CRP,IL-6 and IL-8 in the two groups were lower than those before the treatment;those of the observation group were lower than those of the control group;and the differences were statistically significant(P<0.05).However,there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Roxadustat combined with recombinant human erythropoietin in the treatment of the patients with renal anemia can improve the T cell subsets-related index levels,reduce the levels of inflammatory factors,and increase the levels of Hb,Alb,and SF.M
作者
王静
WANG Jing(Department of Nephrology of the Second Affiliated Hospital of Shenyang Medical College,Shenyang 110036 Liaoning,China)
出处
《中国民康医学》
2021年第23期46-48,共3页
Medical Journal of Chinese People’s Health
关键词
肾性贫血
罗沙司他
重组人促红素
T细胞亚群
炎性因子
白蛋白
铁蛋白
Renal anemia
Roxadustat
Recombinant human erythropoietin
T cell subset
Inflammatory factor
Albumin
Ferritin
